The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice

International Immuno-Oncology Biomarker Working Group

Fingerprint

Dive into the research topics of 'The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice'. Together they form a unique fingerprint.

Medicine & Life Sciences